Cancer Diagnostics Market Trends

  • Report ID: 2550
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Cancer Diagnostics Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Incidence Rates of Cancer and Sedentary Lifestyle

Rising sedentary lifestyles of people living in the developing and developed countries has led to an increase in the number of head, lung and neck cancer cases as a result of improper posture. Additionally, the surge in consumption of tobacco & alcohol is estimated to result in a higher number of cancer cases. Further, the increasing awareness about diagnostics among the masses is predicted to be the main growth driver for the market. Some developing countries following traditional cancer treatment are now looking to adopt modern cancer diagnostic methods for earlier detection. Owing to these factors market is expected to grow during the forecast period.

  • Growing Geriatric Population

Increasing life expectancies in different countries across the world has led to significant growth in the older population. Countries such as Japan and China contain a larger number of elderly populations as a result of improved healthcare, political, economic and social conditions. Consequently, complexity of diagnosis has also increased along with the demand for cancer diagnostics. Owing to these factors, market is expected to grow during the forecast period.

  • Need for Evidence Based Approach towards Cancer Diagnosis

There is substantial evidence available through randomized controlled trials concluding that the adoption of cancer diagnostics could significantly reduce the mortality rate caused by cancer. Additionally, people are becoming more inclined towards evidence based treatments with higher accuracy so that the entire process is swifter and has minimum side effects. On the back of these factors, cancer diagnostics market is anticipated to grow over the next few years.

  • Increasing Research and Development Activities

Extensive research and development activities being carried out by the government organizations and research universities are estimated to open up more opportunities for the sector along with increase the market growth over the forecast period.

  • Technological Advancements

Technological advancements in the fields that lead to the development of highly advanced medical products, equipment and treatments such as endoscopy, biomarkers, biopsy and imaging are predicted to drive the market growth in future.

Challenges

  • Radiation risks from imaging tests

The radiations emitted from various imaging tests could increase the risk of developing a cancer later in the life of the person. This is estimated to negatively affect the market growth over the forecast period. However, newer diagnostic methods are being developed that are better and are anticipated to make this risk negligible.

  • Lack of skilled professionals

Cancer diagnostics require technically skilled professionals. As there is already a dearth of healthcare professionals across the world, it is predicted to hamper the market growth in the forecast period.

 


Base Year

2024

Forecast Year

2025-2037

CAGR

6.2%

Base Year Market Size (2024)

USD 113.89 billion

Forecast Year Market Size (2037)

USD 248.95 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of cancer diagnostics is estimated at USD 119.89 billion.

Cancer Diagnostics Market size was over USD 113.89 billion in 2024 and is poised to exceed USD 248.95 billion by 2037, growing at over 6.2% CAGR during the forecast period i.e., between 2025-2037.

North America industry is anticipated to account for largest revenue share by 2037, backed by increasing geriatric population, rising research and development initiatives by the government, increasing cancer cases among the population and need for evidence based treatment for cancer.

The major players in the market are Siemens Healthcare Gmbh, GE Healthcare, Abbott, Becton, Dickinson & Company, Illumina Inc., Hologic Inc., F.Hoffman-La Roche, Qiagen NV, Phillips Healthcare, CR Bard Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., Biocartis SA, Biocare Medical LLC, Cancer Genetics Inc., Myriad Genetics, and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos